Dr. Blaž Mrevlje joins CardioSignal as Medical Director
October 18, 2024
CardioSignal is pleased to announce the appointment of Dr. Blaž Mrevlje as its new Medical Director. In this role, Dr. Mrevlje will lead medical development at CardioSignal, contributing his expertise in clinical research, regulatory documentation, and medical communication to further advance the company's innovative solutions for heart disease detection.
Dr. Mrevlje brings over 15 years of experience in cardiology, interventional cardiology, and clinical research, having worked at university hospitals across Slovenia, Poland, Germany, and the UK. His comprehensive background spans clinical practice, research, and leadership, making him exceptionally well-suited to help propel CardioSignal's medical initiatives. Most recently, he served as a Clinical Research Physician at Cardialysis, where he played a pivotal role in clinical trials and medical research in cardiology.
"Dr. Mrevlje's depth of experience across various facets of cardiology, combined with his impressive track record in clinical research and medical leadership, makes him the ideal choice to take on the role of Medical Director at CardioSignal. His vision aligns perfectly with our goal of transforming smartphone technology into a reliable, accessible tool for heart disease detection," says cardiologist Dr. Juuso Blomster, CEO and co-founder of CardioSignal.
Dr. Mrevlje has also contributed extensively to academic research, including authoring peer-reviewed publications and presenting at national and international scientific meetings. He has served as a faculty member and panelist at numerous cardiology conferences, and his involvement in regulatory and medical affairs at Novo Nordisk demonstrates his ability to bridge the gap between clinical research and industry. As a member of cardiology societies and an editorial board reviewer for scientific journals, Dr. Mrevlje's influence in the field is well-established.
"Joining CardioSignal presents an exciting opportunity to contribute to the development of cutting-edge technology that can democratize access to heart disease detection. The potential to make impactful changes in patient care using easily accessible smartphone technology is enormous, and I am thrilled to be part of a team that is at the forefront of this innovation," states Dr. Blaž Mrevlje.
Highlights from Dr. Mrevlje’s career:
Clinical Research Physician, Cardialysis B.V., Rotterdam, The Netherlands
Medical Manager, Novo Nordisk, Medical Affairs Team (Europe East and South)
Specialist of Internal Medicine and Interventional Cardiology, various university hospitals in Slovenia, Germany, and the UK
PhD in Interventional Cardiology, Jagiellonian University, Kraków, Poland
Faculty member, panelist, and organizing committee member for multiple international cardiology conferences
Author of peer-reviewed scientific publications and speaker at scientific meetings
CardioSignal is excited to welcome Dr. Mrevlje to the team as we continue to innovate in the field of cardiac health.
Further information:
Dr. Juuso Blomster, CEO, juuso.blomster@cardiosignal.com
Dr. Blaž Mrevlje, Medical Director, blaz.mrevlje@cardiosignal.com
About CardioSignal
CardioSignal develops groundbreaking solutions for detecting heart diseases using digital cardiac biomarkers. The CardioSignal technology utilizes the gyroscope and accelerometer motion sensors to non-invasively measure heart motion to determine cardiac health and function. Originally an academic spin-off, the company’s patented gyrocardiography technology is built on a decade of research and algorithm development. CardioSignal is a brand and a product by Precordior Ltd, an ISO 13485 and 27001 certified health technology company formed in 2017 with operations in Turku, Finland, and Palo Alto, CA, USA.